China National Medicines (SHA:600511) posted 2024 net profit attributable to shareholders of 2.00 billion yuan, or 2.6509 yuan per share, down 6.8% from 2.15 billion yuan, or 2.8443 yuan per share, the previous year.
The revenue of the Sinopharm Group (HKG:1099) unit climbed 1.8% year over year to 50.6 billion yuan from 49.7 billion yuan, according to a filing with the Shanghai bourse.
The company declared a cash dividend of 0.80 per share for 2024.
Shares of China National Medicines were down 2% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。